Analysearchiv
Alle Analysen
Seite 9 von 45 · 1080 Analysen
42/100
Sanofi SA: A Pure-Play in Transition, Still Proving Life After Dupixent
Sanofi is a French pure-play biopharma built around immunology, vaccines, and rare disease after ceding control of Opella. Dupixent alone reached 15.714 billion EUR of 2025 sales, about 36% of group revenue, and still grew 30.8% in Q1 2026, yet the market withholds a growth multiple until a post-Dupixent bridge is proven ahead of the roughly 2031 patent cliff. Rating Hold: a cleaner, cash-generative business at a cheapish multiple with 8.089 billion EUR of 2025 free cash flow, but no wide margin of safety on the hard part of the story.
45/100
BioMarin Pharmaceutical: A Rare-Disease Cash Engine in Transition
BioMarin is a profitable rare-disease biopharma whose enzyme franchise generated about 2.106 billion USD of 2025 revenue and funds the company, while VOXZOGO (926.9 million USD) drives both growth and sentiment. The Amicus acquisition diversified the portfolio into Fabry and Pompe disease and lifted 2026 revenue guidance to 3.825-3.925 billion USD, yet weekly and oral achondroplasia rivals from Ascendis and BridgeBio keep the margin of safety thin. Rating Hold: cash generation and Amicus diversification make BioMarin sturdier than sentiment implies, but VOXZOGO competition caps the upside at today's price.
36/100
Panasonic Holdings: Better Business, Priced Ahead of Proof
Panasonic Holdings is a diversified Japanese electronics group whose earnings base is still mature B2B and appliance operations, while batteries and AI-infrastructure products drive the growth narrative. FY2026 sales were ¥8.05 trillion across six segments, but ROE fell to 3.8% on ¥174.5 billion of restructuring charges, and the shares are up about 68% in 2026 on an AI-infrastructure rerating that capitalizes one hot battery-and-data-center engine across the whole group. Rating Hold: the business mix is genuinely improving, but at ¥4,540 the price already discounts most of the battery, AI-infrastructure, and restructuring upside, leaving no margin of safety against a conservative fair value near ¥2,400-¥2,690.
47/100
Symrise: A High-Quality Compounder Now Priced for Delivery, Not Discovery
Symrise is a scaled, oligopolistic flavors-and-fragrances and nutrition platform that gets paid for being embedded in customers' everyday products, with 2025 sales of €4.93 billion, a 21.9% adjusted EBITDA margin and record €780 million of business free cash flow. The 2026 question is delivery, not discovery: organic growth has cooled from 8.7% in 2024 to low single digits in 2025 and slightly negative in Q1 2026, yet cash conversion, leverage and margin quality all improved, so the franchise is intact while the near-term growth premium is not obviously earned. Rating Hold: a high-quality compounder whose €88.16 price already reflects most of the self-help and recovery, with a more comfortable margin of safety only in the high-€50s to mid-€60s.
47/100
JD.com: A Stronger Retail Core Discounted for the Cost of Transition
JD.com is China's largest self-operated online retailer, built on a supply-chain-first model spanning first-party retail, marketplace services, logistics, health and industrial procurement. Its retail core is strengthening, with JD Retail operating margin up to 5.6% in Q1 2026 and net service revenue growing 20.6% against just 1.0% product growth, yet group profit and cash conversion are obscured by heavy food-delivery and overseas investment, while listed-subsidiary stakes worth about US$17.7 billion anchor a sum-of-the-parts case. Rating Cautious Buy: the market discounts the cost of transition more than it credits a stronger retail core, large buybacks and visible listed stakes.
46/100
FUJIFILM Holdings: A Proven Reinventor Now Tested on Returns, Not Survival
FUJIFILM Holdings is a diversified Japanese technology group earning ¥3.36 trillion of FY2026 revenue across healthcare and Bio CDMO, semiconductor materials, imaging (instax) and office systems. Electronics and Imaging already supply about ¥260.9 billion, roughly three-quarters of segment operating profit, yet Healthcare ROIC is only 1.6%, FY2026 free cash flow is negative amid a capex bulge, and owner earnings near 23 times sit well above the 15.7 times headline P/E. Rating Hold: the transformation from film survivor to multi-engine compounder is real, but healthcare returns and owner earnings still lag the price, leaving no margin of safety until below ¥2,650.
49/100
ACM Research: A Credible China Semicap Franchise, a Demanding Holdco Structure
ACM Research is a Nasdaq-listed holding company whose value is dominated by its roughly 73.6%-owned, Shanghai-listed subsidiary ACM Shanghai, built on a single-wafer wet-cleaning franchise now broadening into plating, furnace, track and PECVD. The parent trades at a steep discount to the quoted value of that stake, yet the A-share quote is already rich, four customers make up 52.2% of 2025 revenue, and first-quarter 2026 free cash flow was negative 52.1 million USD. Rating Hold: strong China semicap execution is real, but at 104.50 USD the price offers too little protection against cash-conversion, policy and holdco-structure risk.
49/100
85Buffett
Bentley Systems: Durable Infrastructure Compounder, Thin Margin of Safety
Bentley Systems is a specialized infrastructure-engineering software vendor whose economic engine is a recurring estate embedded in civil, utility, and owner-operator workflows, with $1.495 billion ARR, 93% recurring revenue, 99% account retention, and 109% net retention. Full-year 2025 revenue rose 11.0% to $1.502 billion and free cash flow reached $520.2 million, yet a dual-class structure leaves the Bentley Control Group with about 62.8% of voting power and the $30 price sits roughly at conservative fair value. Rating Hold: a high-quality, sticky compounder whose cash conversion the headline P/E understates, but founder control and a thin margin of safety make a fresh buy more attractive below $25.
44/100
Black Sesame International: Credible Challenger, Unproven Cash Conversion
Black Sesame is a fabless designer of automotive compute SoCs, selling ADAS chips and bundled solutions; 2025 revenue rose 73% to RMB822 million, yet it stays deeply loss-making with R&D near 1.7x sales. It has crossed the technical-credibility threshold (A1000 shipping in Geely, BYD and FAW models) but not the cash-conversion one, leaning on repeated 2025-2026 equity raises. Rating Hold: real commercialization exists, but recurring dilution and negative owner earnings cap valuation support, with a true margin of safety only below about HK$6.
57/100
88Buffett
Belimo Holding: Ein Premium-HVAC-Compounder mit eingepreister KI-Kühlungs-Perspektive
Belimo ist der Schweizer Pure-Play-Marktführer bei HVAC-Feldgeräten (die Stellantriebe, Regelventile, Sensoren und Zähler, die Heizung, Kühlung und Lüftung regeln) und verkauft über Installations- und Sanierungskanäle mit rund 60% der Umsätze sowie über OEM-Kanäle mit rund 40%, ohne mit den integrierten Gebäudeautomations-Giganten zu konkurrieren, die es beliefert. 2025 stiegen die Umsätze in Lokalwährungen um 23.3% auf CHF 1120.8 Millionen bei einer EBIT-Marge von 20.8% und einem ROIC von 27.8%, da die KI-Rechenzentrums-Flüssigkeitskühlung mit rund 17% der Umsätze zu einem zweiten Wachstumsmotor neben der dauerhaften Energieeffizienz-Sanierungsfranchise wurde, doch bei rund dem 61-fachen der nachlaufenden Gewinne liegt die Aktie nahe dem oberen Rand ihrer eigenen historischen Spanne. Einstufung Beobachten: ein wirklich exzellenter Nischen-Compounder, dessen Preis bereits Exzellenz plus eine lange KI-Kühlungs-Perspektive einpreist, mit einem attraktiveren Einstieg erst unter rund CHF 480.
53/100
80Buffett
Sika AG: Qualitäts-Compounder in einem zyklischen Luftloch
Sika ist der globale Marktführer für Bauchemie (Betonzusatzmittel, Abdichtung, Dichtstoffe, Dach- und Industrieklebstoffe) und verkauft lokal angepasste Systeme über mehr als 400 Werke in über 100 Ländern, mit ergänzenden Übernahmen wie Parex und MBCC fest in das Geschäftsmodell integriert. Der Umsatz 2025 fiel um 4.8% auf CHF 11.20 Mrd. angesichts eines starken Schweizer Frankens und eines schwachen Baukonjunkturzyklus, doch das Wachstum in Lokalwährung blieb positiv und die Materialmarge stieg auf 54.9%, während die MBCC-Synergien CHF 182 Mio. erreichten. Bewertung Halten: ein erstklassiger Serienübernehmer-Compounder gefangen in einem zyklischen Luftloch, aber bei etwa dem 26-Fachen des Gewinns der Vergangenheit preist die Bewertung bereits einen Großteil der Margenerholung ein, bevor das organische Wachstum zurückgekehrt ist.
51/100
81Buffett
NARI Technology: Grid-Control Franchise, Quality Already Priced
NARI is the dominant listed proxy for China's grid-control layer: dispatch software, relay protection, UHV control and energy-management systems built around State Grid. 2025 revenue reached RMB 66.23bn with operating cash flow of RMB 12.77bn, yet revenue is outgrowing profit as the mix shifts toward lower-margin storage and outside-grid work. Rating Hold: a high-quality policy-cycle compounder whose roughly 22x trailing valuation leaves little margin of safety against further mix dilution.
48/100
AVIC Jonhon Optronic: Defense-Grade Interconnect Leader, Recovery Already Priced
AVIC Jonhon is a Chinese high-reliability interconnect maker whose defense-grade connector core still carries the business (connectors are 98.5% of revenue) while EVs, data centers and optics become the larger growth engine. 2025 revenue edged up 3.4% to RMB 21.39 billion but attributable profit fell 35.6% to about RMB 2.16 billion as defense demand softened and gold, copper and silver costs surged, and at RMB 42.69 the stock already trades on a mid-40s trailing multiple that discounts a recovery while cash conversion stays weak. Rating Hold: the franchise is intact and a rebound is plausible, but today's price pre-spends most of it with no margin of safety.
53/100
80Buffett
Straumann Holding AG: Marktführer der Dentalplattform zu einem anspruchsvollen Preis
Straumann ist der weltweite Marktführer für Spezialzahnmedizin, eine Schweizer Plattform, die sich vom Premium-Implantathersteller zu einer Multimarken- und Multipreisgruppe entwickelt hat, die Implantate, digitale Workflows, Biomaterialien, Prothetik und Aligner umfasst, mit CHF 2.61 Milliarden Umsatz 2025 und rund 35% eines CHF 6.0 Milliarden großen Implantatmarkts. Die Qualität der Franchise ist echt (ROCE 30.6%, Eigenkapitalquote 57.6%, ein Jahrzehnt an Marktanteilsgewinnen), aber die Bruttomarge ist von 76.2% auf 68.6% gesunken und die Free-Cashflow-Marge von 21.8% auf 11.1%, da der Value-Tier- und Digital-Mix zunahm, und die Aktie notiert bei rund dem 35.8-Fachen des Kerngewinns bei einer Free-Cashflow-Rendite von 1.7%. Einstufung Halten: ein hochwertiger Compounder mit langer Wachstumsbahn, aber der Preis diskontiert bereits einen Großteil der nächsten Margen- und Ökosystemstufe und lässt wenig Sicherheitsmarge.
52/100
84Buffett
GSK plc: Neu aufgebaute Biopharma, im Wettlauf mit der Patentklippe
GSK plc ist ein britisches Biopharma-Unternehmen, das nach der Haleon-Abspaltung 2022 rund um Impfstoffe und Spezialmedikamente neu aufgebaut wurde, mit einem Umsatz von £32.7 Milliarden im Jahr 2025, verankert durch Shingrix und die ViiV-HIV-Franchise. Spezialmedikamente treiben nun das Wachstum (£13.5 Milliarden, +14% CER im Q1 2026), und der Kernbetriebsgewinn stieg um 11% auf £9.8 Milliarden, doch die gesamte Geschichte hängt davon ab, die Dolutegravir-HIV-Klippe 2028–2030 zu ersetzen, bevor sie eintrifft. Einstufung Halten: eine echt hochwertigere Franchise zu etwa dem 11.6-Fachen des Kerngewinns, aber der Preis nimmt bereits einen Großteil der Patentklippen-Brücke vorweg und lässt wenig Sicherheitsmarge.
60/100
72Buffett
Sungrow Power Supply: Hochwertiges Wachstum in einer zyklischen Hülle
Sungrow Power Supply ist ein gründergeführter globaler Marktführer bei Solarwechselrichtern und Energiespeichersystemen, mit Übersee-Umsätzen von 60.7% des Umsatzes 2025 und Speicherlösungen nun als größtem Segment mit 41.9% der Verkäufe. Der operative Cashflow stieg auf CN¥16.9 Milliarden und die Forderungen verbesserten sich, doch der Umsatz im ersten Quartal 2026 fiel um 18.3% und der Gewinn um 40.1%, was eine scharfe Margen-Mix-Zyklizität hinter der Qualitätsgeschichte offenlegt. Einstufung Halten: eine echte Qualitätswachstumsfranchise, die mit einem Aufschlag gehandelt wird, der wenig Sicherheitsmarge für Ausführungsfehler lässt.
U.S. Market Close Daily | 2026-06-26
Major indexes edged lower as an AI and semiconductor reset outweighed better breadth, cheaper oil, and lower Treasury yields.
42/100
94Buffett
Games Workshop: An Exceptional Warhammer Compounder, Priced for Continued Excellence
Games Workshop is the vertically integrated owner of the Warhammer universe, designing, manufacturing and selling miniatures, paints, books and licensed media from a single UK creative stack at returns on capital few public companies reach. FY2025 delivered £617.5m of total revenue and £262.8m of profit before tax, and FY2026 is guided higher even as the volatile licensing line steps down from £52.5m to at least £30m. Rating Hold: an exceptional IP compounder whose roughly 35x earnings multiple already prepays years of flawless execution, leaving no margin of safety at £217.
38/100
Simulations Plus: A Credible Drug-Modeling Specialist, Now Priced as a Near-Cash Deal Stock
Simulations Plus builds scientifically trusted drug-development modeling software (GastroPlus, MonolixSuite, ADMET Predictor, DILIsym), but its revenue mix has drifted toward lower-margin services since the 2024 Pro-ficiency acquisition, which pulled FY2025 gross margin to 58% and triggered a $77.2m impairment. On 2026-06-26 the equity trades as a near-cash event security: Altaris' agreed $18.50-per-share takeout caps upside just above the $18.14 close, while a broken deal would reopen real downside. Rating Avoid: a thin-spread cash-deal security whose unresolved software-mix question still sits underneath the transaction.
38/100
Carl Zeiss Meditec: A High-Grade Ophthalmology Franchise Forced to Relearn Its Operating Model in China
Carl Zeiss Meditec is a premium German ophthalmology and microsurgery franchise where ophthalmology drives about 77% of sales and recurring revenue has climbed from 9% two decades ago to roughly 50%. A simultaneous China VBP shock and weak Americas equipment demand crushed H1 FY2025/26 adjusted EBITA margin to 6.1% from 10.7%, and the shares have fallen more than 80% from their 2021 peak to 27.96 euros. Rating Watch: a high-quality medtech franchise in a real trough, but the China relisting and margin-restoration bridge is still too unproven for a clean entry, with the ideal buy zone at 24 to 26 euros.
45/100
77Buffett
SAP: A High-Quality Incumbent Late in Its Cloud Migration, Now Priced for Proof Rather Than Possibility
SAP is the incumbent enterprise-applications vendor migrating its captive ERP installed base from license-and-support to cloud subscriptions, where process centrality keeps converting into long-duration economics. In 2025 cloud revenue reached 21.0 billion euros and predictable revenue 86%, with total cloud backlog of 77.3 billion euros, yet FY2026 guidance for slightly decelerating current-backlog growth reset the stock more than 50% below its early-2025 peak to about 21.5x earnings. Rating Hold: the cloud transition is genuinely working and the franchise is high quality, but at today's price the market already asks for proof rather than possibility, with the ideal buy zone at 95 to 101 euros.
42/100
Shimano: A Fortress Cycling Franchise in a Real Trough, But the Price Already Pays for the Repair
Shimano is a century-old Japanese precision manufacturer whose bicycle drivetrain and braking franchise still drives roughly three-quarters of group sales, with fishing tackle the resilient second engine. Group operating income has fallen from a 169.2 billion yen pandemic peak in 2022 to a guided 47.0 billion yen in 2026 (margin near 10% against a historical 20% to 25%), and at 17,340 yen (about 35x guided earnings) the price already discounts much of the eventual repair, leaving no margin of safety. Rating Hold: a fortress-quality franchise in a real but uncertain trough, where the moat is intact yet the entry price is not yet compelling, with the ideal buy zone at 12,000 to 14,000 yen.
51/100
83Buffett
Hengrui Pharmaceuticals: A Fortress Innovation Platform, But RMB 50 Already Pays for the Upgrade
Hengrui Pharmaceuticals is China's largest listed innovative-drug platform, still earning mainly from domestic drug sales while its valuation increasingly rests on converting self-funded R&D into commercial franchises and recurring overseas licensing income. 2025 revenue reached RMB 31.63 billion with net profit of RMB 7.71 billion and a fortress balance sheet holding RMB 40.16 billion of cash, yet at RMB 50.04 (about 41x trailing earnings) the price sits above the conservative fair value and leaves no margin of safety. Rating Hold: a rare high-quality China pharma platform already priced for an innovation-monetization upgrade it has not yet fully earned.
U.S. Market Close Daily | 2026-06-25
U.S. stocks closed mixed in a sector-rotation tape as semiconductor strength offset pressure from mega-cap consumer technology and sticky inflation kept rate risk in focus.